Trial Profile
Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2021
Price :
$35
*
At a glance
- Drugs Bromocriptine (Primary) ; Tolcapone (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 12 Nov 2021 Planned End Date changed from 1 Jan 2018 to 31 Jan 2018.
- 12 Nov 2021 Planned primary completion date changed from 1 Jan 2018 to 31 Jan 2018.
- 12 Nov 2021 Status changed from completed to withdrawn prior to enrolment.